| 1 |
Desnick, RJ, Ioannou, YA, Eng CM. Alpha galactosidase A deficiency: Fabry disease [M]//Scriver CR, Beaudet AL, Sly WS,et al. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill, 2001: 3733-3774.
|
| 2 |
Germain DP. Fabry disease [J]. Orphanet J Rare Dis, 2010, 5: 30.
|
| 3 |
Ashton-Prolla P, Tong B, Shabbeer J, et al. Fabry disease: twentytwo novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes [J]. J Investig Med, 2000, 48(4):227-235.
|
| 4 |
Shabbeer J, Yasuda M, Benson SD, et al. Fabry disease:identification of 50 novel alpha-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations [J]. Hum Genomics, 2006, 2(5): 297-309.
|
| 5 |
陈佳韵，王朝晖，潘晓霞，等. Fabry病家系的α-半乳糖苷酶A基因突变研究 [J]. 中华肾脏病杂志, 2005, 21(11): 654-658.
|
| 6 |
Lv YL, Wang WM, Pan XX, et al. A successful screening for Fabry disease in a Chinese dialysis patient population [J]. Clin Genet, 2009, 76(2): 219-221.
|
| 7 |
MacDermot KD, Holmes A, Miners AH, et al. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males [J]. J Med Genet, 2001, 38(11): 750-760.
|
| 8 |
刘和俊,曹克将,李诚让,等. 肥厚型心肌病样临床表现的Fabry病家系研究[J]. 中华心血管病杂志, 2006, 34(2): 143-147.
|
| 9 |
吕轶伦，陈佳韵，潘晓霞，等. α-半乳糖苷酶A 活性检测与Fabry病诊断筛查[J]. 诊断学理论与实践，2007，6(5): 417-420.
|
| 10 |
Sessa A, Toson A, Nebuloni M, et al. Renal ultrastructural findings in Anderson-Fabry disease [J]. J Nephrol, 2002,15(2):109-112.
|
| 11 |
Vedder AC, Linthorst GE, van Breemen MJ,et al. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels[J]. J Inherit Metab Dis, 2007, 30(1): 68-78.
|
| 12 |
Paschke E, Fauler G, Winkler H, et al. Urinary total globotriaosylceramide and isoforms to identify women with Fabry disease: a diagnostic test study [J]. Am J Kidney Dis, 2011, 57(5):673-681.
|
| 13 |
Aerts JM, Groener JE, Kuiper S, et al. Elevat ed globotriaosylsphingosine is a hallmark of Fabry disease [J]. Proc Natl Acad Sci U S A, 2008, 105(8): 2812-2817.
|
| 14 |
Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease [J]. N Engl J Med, 2001, 345(1): 9-16.
|
| 15 |
Schiffmann R, Kopp JB, Austin HA 3 rd, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial [J]. JAMA, 2001, 285(21): 2743-2749.
|
| 16 |
Fabrazyme (agalsidase beta) European Public Assessment Report(EPAR)[EB/OL]. (2012-02-02)[2012-05-29]. http://www.emea.europa.eu/humandocs/Humans/EPAR/fabrazyme/fabrazyme.htm.
|
| 17 |
Replagal (agalsidase alfa) European Public Assessment Report(EPAR) [EB/OL]. (2012-03-19)[2012-05-29]. http://www.emea.europa.eu/humandocs/Humans/EPAR/replagal/replagal.htm.
|
| 18 |
Eng CM, Germain DP, Banikazemi M, et al. Fabry disease:guidelines for the evaluation and management of multi-organ system involvement [J]. Genet Med, 2006, 8(9): 539-548.
|
| 19 |
Hughes DA, Ramaswam U, Elliott P, et al. Guidelines for the diagnosis and management of Anderson-Fabry disease [EB/OL].[2012-05-29]. http://www.specialisedservices.nhs.uk/library/23/Guidelines_for_Anderson_Fabry_Disease.pdf
|
| 20 |
Fan JQ, Ishii S, Asano N, et al. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor [J]. Nat Med, 1999, 5(1):112-115.
|
| 21 |
Shin SH, Murray GJ, Kluepfel-Stahl S, et al. Screening for pharmacological chaperones in Fabry disease [J]. Biochem Biophys Res Commun, 2007, 359(1): 168-173.
|
| 22 |
Yam GH, Bosshard N, Zuber C, et al. Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by traffickingincompetent variants [J]. Am J Physiol Cell Physiol, 2006, 290(4):C1076-C1082.
|
| 23 |
Germain DP, Fan JQ. Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies [J]. Int J Clin Pharmacol Ther, 2009, 47 Suppl:S111-S117.
|